[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338509-105":59,"doc-detail-338509-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pharmacokinetics-of-infigratinib-and-its-active-metabolites-in-chinese-patients-with-advanced-gastric-cancer-harboring-fgfr2-gene-amplification","Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification","","Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, shows activity in tumors with FGFR alterations. This phase II, open-label, single-arm study assessed pharmacokinetics of infigratinib and major metabolites in Chinese patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma carrying FGFR2 gene amplification. Patients received 125 mg once daily using 3 weeks on/1 week off dosing over 28-day cycles. Plasma PK parameters were derived with a non-compartmental model from 21 patients. After single dosing, median time to Cmax was 3.1 h (Cmax 85.9 ng/mL), and exposure over time (AUC0-t) reached 637 h·ng/mL. After 21-day dosing, steady-state Cmax,ss occurred at 4.0 h (204 ng/mL) with AUC0-24,ss of 3060 h·ng/mL; a steady state formed by day 15.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pharmacokinetics-of-infigratinib-and-its-active-metabolites-in-chinese-patients-with-advanced-gastric-cancer-harboring-fgfr2-gene-amplification/338509/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pharmacokinetics-of-infigratinib-and-its-active-metabolites-in-chinese-patients-with-advanced-gastric-cancer-harboring-fgfr2-gene-amplification/338509.png","ImageObject",300,407,{"name":92,"@type":93},"Evangeline","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What population and disease setting were studied for infigratinib pharmacokinetics?","Question",{"text":112,"@type":113},"Chinese patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification were evaluated.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What dosing regimen was used in the phase II study?",{"text":117,"@type":113},"Patients received 125 mg infigratinib orally once daily on a 3 weeks on, 1 week off schedule for 28-day cycles.",{"name":119,"@type":110,"acceptedAnswer":120},"How were pharmacokinetic parameters analyzed in this study?",{"text":121,"@type":113},"Plasma PK parameters were calculated using a non-compartmental model.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338509,1790150684,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},13056703019662,"https://ap-avatar.wpscdn.com/avatar/be000253a8e92610077?_k=1778726343310543188","DOI: 10. 1111/cts.70091  \nARTICLE  \nPharmacokinetics ofinfigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification  \nJiajia Yuan1 | Lin Shen1 | Tian Shu Liu2 | HuiTing Xu3 | Jianwei Yang4 | Jia Wei5 | Haiping Jiang6 | Yanhong Deng7 | Hongming Pan8 | Yusheng Wang9 | Xiaotian Zhang1 | Zhi Peng1 | Changsong Qi1 | Lingli Zhang10  | Peiwen Hsu10 | Lin Song10  | Lei Mu10 | Qiao Sun10  | Jifang Gong1 | Cheng Lyu10  \n1Peking University Cancer Hospital and Institute, Beijing, China  \n2Zhongshan Hospital Affiliated to Fudan University, Shanghai, China 3Hubei Cancer Hospital, Wuhan, China 4Fujian Provincial Cancer Hospital, Fuzhou, China  \n5Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China  \n6The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China  \n7The Sixth Affiliated Hospital, Sun Yatsen University, Guangzhou, China 8Sir Run Run Shaw Hospital affiliated with Zhejiang University School of  \nMedicine, Hanzhou, China 9Shanxi Cancer Hospital, Taiyuan, China  \n10Shanghai LianBio Development Co., Ltd, Shanghai, China  \nCorrespondence  \nJifang Gong, GI Oncology Department, Peking University Cancer Hospital and Institute, Fucheng Road No. 52 (Dinghui Temple), Beijing 100142, China. [Email:](Email: goodjf@163.com)[ goodjf@163.com](Email: goodjf@163.com)  \nCheng Lyu, R&D, Shanghai LianBio Development Co., Ltd., Hubin Road No.  \n150, Shanghai 200021, China.  \nEmail: [levvy.lv@aliyun.com](levvy.lv@aliyun.com)  \nAbstract  \nInfigratinib, an FGFR1-3 selective oral tyrosine kinase inhibitor, has shown clinical activity in cancers with FGFR alterations. The pharmacokinetics (PK) of infigratinib and its major metabolites have been characterized in global populations. This study examined the PK profile of infigratinib and its metabolites in Chinese patients. In this phase II, open-label, single-arm study in China, patients with advanced gastric cancer (GC) or gastroesophageal junction adenocarcinoma (GEJ) harboring FGFR2 gene amplification received 125 mg infigratinib orally once daily in a “3 weeks on, 1 week off” schedule for 28-day cycles. Plasma PK parameters were calculated with a non-compartmental model. Data were available from 21 patients (19 GC and two GEJ) . After a single dose, peak infigratinib plasma concentration was reached at a median time of 3.1 h, with geometric mean Cmax of 85.9 ng/mL and AUC0-t of 637 h*ng/mL. After 21-day dosing, geometric mean infigratinib Cmax,ss of 204 ng/mL was reached at a median of 4.0 h; geometric mean AUC0-24,ss was 3060 h*ng/mL. The geometric mean Rac,Cmax (%CV) andRac,AUC0-24 (%CV) of infigratinib was 2.5 (113.8) and 5.1 (138.2), respectively. A steady state of infigratinib was reached after continuous dosing for 15 days. The metabolites accounting for >10% of infigratinib were BHS697 and CQM157 . The PK profiles of infigratinib and its metabolites in Chinese patients with GC or GEJ were largely consistent with known PK profiles ofinfigratinib from global populations.  \nStudy Highlights  \nWHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?  \nThe pharmacokinetic profile of infigratinib has been reported in a global phase I study and in patients with cholangiocarcinoma. However, those were done in predominantly Western patients and the pharmacokinetic profile of infigratinibin Chinese patients has not been reported.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.  \n© 2024 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.  \nClin Transl Sci. 2024;17:e70091 .  \n[https://doi.org/10.1111/cts.70091](https://doi.org/10.1111/cts.70091)  \n[www.cts-journal.com](","cbCaii9KsYEXgdET","https://ap.wps.com/l/cbCaii9KsYEXgdET","pdf",265841,11,"English","# Abstract\n## Study Highlights\n## Introduction","[{\"question\":\"What population and disease setting were studied for infigratinib pharmacokinetics?\",\"answer\":\"Chinese patients with advanced gastric cancer or gastroesophageal junction adenocarcinoma harboring FGFR2 gene amplification were evaluated.\"},{\"question\":\"What dosing regimen was used in the phase II study?\",\"answer\":\"Patients received 125 mg infigratinib orally once daily on a 3 weeks on, 1 week off schedule for 28-day cycles.\"},{\"question\":\"How were pharmacokinetic parameters analyzed in this study?\",\"answer\":\"Plasma PK parameters were calculated using a non-compartmental model.\"}]","Pharmacokinetics of infigratinib and its active metabolites in Chinese patients with advanced gastric cancer harboring FGFR2 gene amplification | PDF",1790023948,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0affa0db2927d6c65b7916c5b394961c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/01b989a7c1c6eabe4e0cfaf432068b91.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/616989515416d1d4d54bea4e4a4fbff1.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a7d3665235986e7d86bf6f346971561.webp",980,1287]